• 17.10.2019 – 17:34

  Fördergesellschaft IZB mbH

  

  The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB

  more

  One document

• 02.04.2019 – 13:44

  Daiichi Sankyo

  Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

  Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction ...

  more

• 28.02.2019 – 13:00

  Daiichi Sankyo Europe GmbH

  Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

  Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...

  more

• 07.01.2019 – 08:01

  Daiichi Sankyo Europe GmbH

  Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

  Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...

  more

• 03.12.2018 – 09:56

  Grünenthal Gruppe

  Grünenthal closes deal with AstraZeneca for Nexium and Vimovo

  Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (EUR 811 m). "Today is an important day for Grünenthal," said Gabriel Baertschi, CEO Grünenthal. "This transaction represents a significant step towards our vision of creating a world free ...

  more

• 30.10.2018 – 08:43

  Grünenthal Group

  Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

  Aachen (ots) - - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need [1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Grünenthal today announced that it has agreed to acquire AstraZeneca's European ...

  more

• 28.08.2018 – 13:36

  Grünenthal Group

  Duzallo®, a fixed-dose combination therapy for gout, approved in Europe

  Aachen (ots) - Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of ...

  more